Background: This study is part of the Innovations in Data, Evidence and Applications for Persons with Neurological Conditions project to understand the strengths, preferences, and needs of persons with neurological conditions living in Canada. Objective: To estimate the prevalence and describe the sociodemographic and clinical characteristics of persons with multiple sclerosis in Canadian home care, nursing home, Complex Continuing Care hospitals, and inpatient mental health care settings. Methods: Cross-sectional study of adults aged 18 years and older with multiple sclerosis (MS; n = 11,250) across Canada from 1996 through 2011 using interRAI Resident Assessment Instrument (RAI) comprehensive health assessments (RAI Minimum Data Set 2.0, RAI-Home Care, RAI-Mental Health). Comparisons were made to adults with Alzheimer's disease and related dementias (n = 260,910), other neurological conditions (n = 163,578) and non-neurological conditions (n = 571,567). Results: The prevalence of MS was highest in Complex Continuing Care hospitals (4125 cases per 100,000 patients), followed by home care (2020 cases per 100,000 patients), nursing homes (1424 cases per 100,000 patients), and mental health settings (138 cases per 100,000 patients). Persons with MS experienced greater impairment in the completion of activities of daily living, pain, pressure ulcers, swallowing difficulty, depression, and anxiety compared with peers within care settings. There were also significant differences between settings, particularly the degree of physical and cognitive impairment experienced by persons with MS. Conclusions: Except for mental health care settings, the prevalence of MS in community, institutional and hospitalbased care settings exceeded that of the general population. These data describing the sociodemographic and clinical characteristics of persons with MS may be used to inform clinical practice and policy decisions for persons with MS across the continuum of care. RÉSUMÉ: Profil clinique des personnes atteintes de sclérose en plaques à travers la gamme complète des soins. Contexte: Cette étude fait partie du projet Innovations in Data, Evidence and Applications for Persons with Neurological Conditions dont le but est de comprendre les forces, les préférences et les besoins des personnes atteintes de maladies neurologiques vivant au Canada. Objectif: Le but de cette étude était d'estimer la prévalence et de décrire les caractéristiques sociodémographiques et cliniques des personnes atteintes de sclérose en plaques (SP) vivant à domicile, dans des résidences pour malades chroniques, des hôpitaux offrant des soins continus complexes et des institutions pour personnes atteintes de problèmes mentaux. Méthodologie: Nous avons effectué une étude transversale portant sur des adultes âgés de 18 ans et plus, qui étaient atteints de SP (n = 11 250) à travers le Canada entre 1996 et 2011. Nous avons utilisé les InterRAI Resident Assessment Instrument (RAI) Comprehensive Health Assessments (RAI Minimum Data Set 2.0, RAI-Home Care, RAI-Mental Health). Nous avons comparé les adultes atteints de SP à des adultes atteints de la maladie d'Alzheimer et d'affections connexes (n = 260 910), d'autres maladies neurologiques (n = 163 578) et de maladies autres que neurologiques (n = 571 567)
maintaining their physical and mental well-being. Long-term care refers to a continuum of services that may be delivered in community (e.g. home care, day programs) or institutional (e.g. nursing home care) settings. 2, 3 In the United States, several studies have evaluated the clinical and demographic characteristics of persons with MS admitted to Medicare-and Medicaid-certified nursing homes. [4] [5] [6] Compared with other nursing home residents, persons with MS were younger at admission and more physically disabled, but less cognitively impaired. 4 Depression was common at admission and it increased substantially in the year after admission, yet most persons with MS did not receive mental health services. 5, 6 These findings raise questions about the quality of care for persons with MS in these settings, both in the availability of mental health services and providers' capacity to respond to the psychosocial needs of this patient population. Further, it is uncertain how persons with MS who receive care in institutional settings may differ from those who receive long-term care services in the community, a question of importance to patients, their families, and policy makers.
In Canada, interRAI Resident Assessment Instrument (RAI) assessments are used as part of routine clinical practice in home care, nursing home, Complex Continuing Care (CCC) hospitals, and inpatient psychiatry. Data from these assessments populate the Continuing Care Reporting System, Ontario Association of Community Care Access Centres Home Care Database, and the Ontario Mental Health Reporting System. 7-10 The interRAI assessment system includes a suite of comprehensive clinical assessments that are compatible across health care settings to collect person-level data in domains such as physical functioning, cognition, mood and behavior, social functioning, disease and health conditions, health service, and medication utilization. [11] [12] [13] Widespread implementation of interRAI assessments in Canada 7, 8 provides an opportunity to compare the clinical characteristics of persons with MS across multiple care settings. Substantial international adoption of inter-RAI assessments also permits national comparisons of clinical features and care provision for persons with MS. 13 The Innovations in Data, Evidence and Applications for Persons with Neurological Conditions project was conducted to estimate the cross-sector prevalence, clinical characteristics, and needs of persons with eleven neurological conditions living in Canada. The present study provides prevalence estimates and a clinical profile of individuals affected by MS across four care settings: inpatient mental health, home care, nursing home, and CCC hospitals.
METHODS

Data Sources
Continuing Care Reporting System
Nursing homes and CCC hospitals in nine Canadian provinces and territories have implemented the RAI Minimum Data Set (RAI-MDS 2.0) or its successor the interRAI Long Term Care Facility assessment (being implemented in New Brunswick). All individuals with a length of stay of 14 days or longer are assessed with the RAI-MDS 2.0, providing near census-level health information on individuals within these care settings. Implementation dates differ by province, and two (Alberta and New Brunswick) had not begun to submit data to the Canadian Institute of Health Information at the time of this study. The nursing home cohort comprises the most recent assessments for unique individuals completed from July 1, 2003 , to March 31, 2011 (Table 1) .
Ontario Association of Community Care Access Centres Home Care Database
Individuals who are expected to use home care services provided by one of Ontario's 14 Community Care Access Centres for 60 days or longer, representing one-third of clients, are evaluated using the RAI-Home Care (RAI-HC). 15 The home care cohort includes the most recent assessments for unique individuals from January 1, 2002, to December 31, 2010 (Table 1) . Although RAI-HC data are available for other provinces, only the Ontario data were used because it was the only province to include home care data on all neurological conditions of interest for the larger project for which this study was conducted.
Ontario Mental Health Reporting System
All Ontario inpatient mental health patients across 55 hospitals and 13 specialty psychiatric facilities are assessed using the RAI-Mental Health (RAI-MH). 16 The mental health cohort includes the most recent admission assessments for unique individuals hospitalized from October 1, 2005, to March 21, 2010 ( Table 1) .
Clinical Scales and Items
The RAI-MDS 2.0, RAI-HC, and RAI-MH instruments share a common set of items and validated clinical scales to assess patients across a broad range of health domains, including physical functioning, cognition, mood and behavior, social functioning, diseases and conditions, health service, and medication utilization. 11, 13 The Cognitive Performance Scale (CPS) is a measure of cognitive impairment that ranges from 0 (intact) to 6 (very severely impaired). [17] [18] [19] The Depression Rating Scale (DRS) is a depression screening instrument derived from seven mood items. The DRS ranges from 0 to 14; scores of 3 or greater indicate depressive disorders. 20 The Activities of Daily Living Hierarchy Scale is a measure of functional performance that ranges from 0 (no impairment) to 6 (total dependence) based upon the ability to complete early and late loss activities of daily living (ADLs). 21 The pain scale ranges from 0 (no pain) to 3 (excruciating pain) and is a highly predictive of visual analog scale pain scores. 22 Finally, the Changes in Health, End-Stage Disease, Signs and Symptoms Scale is a measure of health instability that is predictive of mortality and ranges from 0 (no health instability) to 5 (very high health instability). 23.24 Despite substantial overlap across interRAI instruments, it is important to note that the RAI-MH differs from the RAI-MDS 2.0 and RAI-HC instruments in its collection of information on appetite, pressure ulcers, and psychotropic drug use. For this reason, results on these items are not presented for patients in the mental health cohort.
Identification of Persons with MS
Persons with an MS diagnosis were identified based on pick list item responses on the RAI-MDS 2.0, RAI-HC, and free-text International Statistical Classification of Diseases and Related Health Problems, Tenth Revision, Canada (ICD-10-CA) fields on the RAI-MH instrument. Clinicians are instructed to complete these assessments using all sources of information available. Although most information may be obtained through patient interview and observation, medical records (i.e. physician orders, laboratory data, medication records, and care plans), family members, and the attending physician may also be consulted to complete the assessment. Previous work has established the validity of these methods for identifying persons with an MS diagnosis compared with diagnoses listed on administrative hospital records. 25, 26 Instruments relying on pick list responses achieved very high sensitivity (90%-94%), specificity (99%-100%), and interrater agreement (kappa = 0.76-0.84). 25 The RAI-MH, which relies on ICD-10-CA code responses, also performed well with a sensitivity of 77%, specificity of 100%, and kappa of 0.61. 25 MS prevalence estimates in Canada using the entire history of patient administrative health records were found to be comparable to estimates based RAI MDS 2.0, RAI-HC, and RAI-MH index assessments alone. 27 
Comparison Groups
Four groups were identified for comparison in this study: MS; Alzheimer's disease and related dementias (ADRD); other neurological conditions; and non-neurological conditions. The ADRD group comprised individuals identified with an ADRD diagnosis using the pick list and ICD-10-CA methods previously detailed for those with MS. The other neurological conditions group included individuals identified using interRAI assessments as having a diagnosis of one or more priority conditions included in the Public Health Agency of Canada's National Population Health Study of Neurological Conditions, except ADRD. 28 These diagnoses were Parkinson's disease, epilepsy, traumatic brain injury, Huntington's disease, spinal cord injury, amyotrophic lateral sclerosis, muscular dystrophy, cerebral palsy, and stroke. 29 Finally, individuals without a diagnosis of MS, ADRD, or any of the previously forementioned neurological conditions formed the non-neurological condition comparison group. Note that several conditions including congenital neurological deficit, neuropathy, migraine, tension headache, and other neurological conditions are not included in interRAI assessments, so individuals with these conditions may appear in any of the four study groups. With the exception of the non-neurological conditions group, group assignment was not mutually exclusive. Individuals with comorbid neurological conditions, including MS and ADRD, may appear in multiple groups. Table 2 details the composition of the other neurological conditions comparison group. 
Analysis
Demographic and clinical characteristics of persons with MS, ADRD, other neurological conditions, and non-neurological conditions were compared within and across care setting using items and scales in the RAI-MDS 2.0, RAI-HC, and RAI-MH instruments. Chi-square tests were performed both between groups within each of the four care setting cohorts and within groups between the four care setting cohorts to ascertain the statistical significance of group and setting frequency differences. Given the large number of statistical tests performed, a Bonferroni correction was made. 30 This yielded an adjusted alpha of 0.05∕105 = 0.0005 per test. In part because of the large sample sizes used in this study, only demographic and clinical characteristic comparisons that were significant to an alpha level of 0.0001 were reported. In all care settings, the most recent assessment for each individual was included in the sample used to calculate group demographic and clinical characteristics.
To estimate the point prevalence of MS in each of the four care settings, a prevalence sample comprising Ontario patients receiving care in one of the four care settings on July 1, 2009 (index date) was created. This index date was selected because there was complete interRAI assessment coverage across the four care settings in Ontario at that time. For patients in nursing homes, CCC hospitals, and mental health settings, facility admission and all-cause discharge dates were used to determine inclusion in the prevalence sample. Home care patients in Ontario may remain on service for long periods without actively receiving home care services (e.g. home health aide or nursing visits). To restrict the prevalence sample to patients actively receiving home care services, only patients with a home care referral date before the index date and a RAI-HC assessment completed 180 days before or after the index date were included. Where all-cause discharge dates were available for home care patients, this information was also used to determine inclusion in the secondary sample. The number of individuals included in the denominator for each of the care settings was 110,123 in home care, 68,060 in nursing homes, 4945 in CCC hospitals, and 4360 in mental health settings.
All analyses were conducted using SAS, version 9.2, SAS Institute Inc., Cary, NC. . In all four care settings, persons with MS were predominantly female and were younger than other persons in these settings (Table 3) .
RESULTS
Across
Clinical Measures and Scales
Rates of moderate to severe cognitive impairment (CPS 3+) were higher in institutional settings than in the community. Fewer persons with MS in the home care and mental health cohorts had moderate to severe cognitive impairment compared with 39.6% in nursing homes and 42.3% in CCC hospitals (Table 4 ). Within all four care settings, persons with MS were less likely to have moderate to severe cognitive impairment (CPS 3+) compared with the ADRD and other neurological conditions comparison groups; however, their rates were consistently higher than in the non-neurological comparison group (Table 4) .
Persons with MS in the nursing home and CCC cohorts were less independent in completing ADLs compared with those with MS in the home care and mental health cohorts. The percentage of patients with moderate to severe ADL impairment (Activities of Daily Living Hierarchy Scale 3+) was 13.1% of the mental health cohort and 38.8% of the home care cohort compared with 91.2% of the nursing home cohort and 89.4% of the CCC cohort (Table 4 ). Except for in mental health settings, persons with MS were more likely to be moderate to severely functionally impaired compared with the non-neurological conditions, ADRD, and other neurological conditions comparison groups in each setting ( Table 4 ).
Mobility and Falls
Except in the mental health cohort, persons with MS were more likely to use a wheelchair than the ADRD, non-neurological conditions, and other neurological conditions comparison groups ( Table 5 ). Irrespective of method of ambulation, 38.1% of persons with MS in home care fell in the 90 days before assessment. Fall assessment time frames differ on the RAI-MDS 2.0 and RAI-HC assessment. In the mental health cohort, 17.9% of persons with MS experienced a fall in the 30 days before assessment compared with 10.0% in CCC and 6.4% in nursing homes ( Table 5 ). Within the mental health and home care setting cohorts, the rate of falls by persons with MS was similar to the ADRD and other neurological conditions comparison groups. However, within the nursing home and CCC cohorts, where they were likely to be wheelchair users, persons with MS were least likely of all groups to have experienced a recent fall ( Table 5 ).
Mental Health Issues and Psychotropic Drug and Restraint Use
Across care settings, persons with MS were most likely to show signs of depression (DRS 3+) in the mental health (62.4%), nursing home (28.9%), and CCC (24.6%) care settings ( Table 6 ). Within settings, persons with MS were generally more likely to show signs of depression compared with the other neurological conditions comparison group, but less likely to show signs of depression compared with the ADRD group (Table 6 ).
In the mental health cohort, 59.0% of persons with MS displayed anxiety symptoms compared with 12.9% in home care, 33.4% in nursing home, and 25.7% in CCC (Table 6 ). In the nursing home cohort, 28.7% of persons with MS displayed aggressive behaviors compared with 25.3% in mental health, 21.8% in CCC, and 4.2% in home care. Within all settings, persons with MS were less likely to have aggressive behaviors compared with the ADRD and other neurological conditions comparison groups (Table 6) .
Except for the non-neurological conditions comparison group in the home care cohort, within care settings, persons with MS were least likely of all groups to be prescribed antipsychotic medications (Table 6 ). Conversely, within settings, persons with MS were most likely of all groups to be prescribed antidepressant medications. The same was true for anxiolytic and sedative medications, except in the CCC cohort (Table 6) .
Care by a social worker or psychologist was infrequently provided outside of the mental health setting. Only persons with MS in the home care cohort were more likely than other groups to have contact with a social worker or psychologist on one or more occasions in the past 7 days (Table 6 ).
In the nursing home and CCC cohorts, a similar proportion of persons with MS were restrained with a mechanical restraint or chair that prevents rising in the 7 days preceding assessment (26.5% and 25.3%, respectively; Table 6 ). These rates are similar for the ADRD group in these two settings; however, in mental health only, 6.6% of persons with MS were restrained in the 3 days preceding assessment compared with 24.1% in the ADRD group (Table 6 ).
DISCUSSION
This cross-sectional study establishes disease prevalence estimates and clinical profiles for persons with MS across the Canadian continuum of care. Using ADRD, other neurological conditions, and non-neurological conditions comparison groups, this study also differentiates persons with MS from other individuals within each of the care settings.
Several recent systematic reviews have summarized the epidemiological literature reporting the prevalence of MS among the general population in the North and South America, 31 Europe, 32 Africa, and Asia-Pacific 33 regions. The current study aimed to estimate the prevalence of MS among individuals receiving care in community, institutional, and hospital-based care settings. Given that admission to these care settings is largely dependent on demonstrated need for formal care as a result of disability or illness, it is expected that the prevalence of MS in these care settings would be greater than among the general population. The prevalence of MS in the home care, nursing home, and CCC care settings in this study was approximately 7 to 21 times greater than in the Canadian general population, which ranges between 195 and 298 cases per 100,000 patients. [34] [35] [36] [37] [38] The prevalence of MS among individuals in the mental health cohort was similar to that of the general population, likely because this care setting is oriented toward caring for patients with psychiatric conditions rather than physical disabilities. It has also been hypothesized that mental health Unless otherwise noted, the chi-square p values for group comparisons performed within and across settings are less than 0.0001. facilities may not have the capacity to attend to the medical complexity of persons with MS, 27 thereby reducing access to psychiatric care for persons with MS who are more likely to have comorbid mental health conditions. 39 The results of this study illustrate that MS is a complex neurological condition that affects domains of health and wellbeing beyond physical and cognitive impairment. Most notable are mental health issues such as depression and anxiety. 
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